To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes

• Status: Completed
• Trial end date: 2011-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the safety and tolerability of AZD5658 following ascending single oral doses in Type 2 Diabetics. It will also estimate the maximum tolerated dose.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca

Criteria

Inclusion Criteria:

• Patients must be of non-childbearing potential.

• Body mass index between greater than or equal to 19 and less than or equal to 40 kg/m2

• Patients with confirmed Type 2 Diabetes diagnosis for at least 1 year and treated with Metformin

Exclusion Criteria:

• Clinically significant illness or clinically relevant trauma within 2 weeks before the first administration of the IP

• Participation in another clinical study during the last 30 days prior to enrollment

• Significant cardiovascular event within the last 6 months prior to enrollment